NASDAQ:AEMD Aethlon Medical (AEMD) Stock Price, News & Analysis $0.66 -0.02 (-2.25%) As of 03:12 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Aethlon Medical Stock (NASDAQ:AEMD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aethlon Medical alerts:Sign Up Key Stats Today's Range$0.64▼$0.6850-Day Range$0.67▼$3.0752-Week Range$0.64▼$27.40Volume64,905 shsAverage Volume324,387 shsMarket Capitalization$1.55 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingReduce Company Overview Aethlon Medical, Inc. (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings. The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components. Aethlon has advanced the device through human clinical trials, exploring its potential in patients with viral infections—such as hepatitis C and COVID-19—and in oncology patients where tumor‐derived exosomes contribute to immune system evasion. The company continues to refine its technology, pursue regulatory designations, and seek strategic collaborations to expand its clinical development efforts. Headquartered in San Diego, California, Aethlon Medical was established with a mission to bring innovative extracorporeal therapies to market. Under the leadership of President and Chief Executive Officer Phillip D. Borden, the company engages with regulatory agencies and research institutions across North America and internationally. Aethlon’s research and development operations are complemented by partnerships aimed at accelerating the clinical evaluation of its platform and ultimately delivering new treatment options for patients with urgent medical needs.AI Generated. May Contain Errors. Read More Aethlon Medical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks9th Percentile Overall ScoreAEMD MarketRank™: Aethlon Medical scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingReduce Consensus RatingAethlon Medical has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageAethlon Medical has only been the subject of 1 research reports in the past 90 days.Read more about Aethlon Medical's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aethlon Medical are expected to grow in the coming year, from ($2.11) to ($0.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aethlon Medical is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aethlon Medical is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAethlon Medical has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aethlon Medical's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.28% of the float of Aethlon Medical has been sold short.Short Interest Ratio / Days to CoverAethlon Medical has a short interest ratio ("days to cover") of 0.84, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aethlon Medical has recently increased by 16.60%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAethlon Medical does not currently pay a dividend.Dividend GrowthAethlon Medical does not have a long track record of dividend growth. News and Social Media1.6 / 5News Sentiment0.53 News SentimentAethlon Medical has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Aethlon Medical this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for AEMD on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Aethlon Medical to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aethlon Medical insiders have not sold or bought any company stock.Percentage Held by Insiders0.71% of the stock of Aethlon Medical is held by insiders.Percentage Held by Institutions1.99% of the stock of Aethlon Medical is held by institutions.Read more about Aethlon Medical's insider trading history. Receive AEMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aethlon Medical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AEMD Stock News HeadlinesAethlon MedicalJuly 13, 2026 | fool.comAethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®July 13, 2026 | prnewswire.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.July 17 at 1:00 AM | Banyan Hill Publishing (Ad)Aethlon Medical (NASDAQ:AEMD) Share Price Crosses Below 200 Day Moving Average - Should You Sell?July 9, 2026 | americanbankingnews.comAethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ RulesJuly 6, 2026 | prnewswire.comAethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier®June 26, 2026 | prnewswire.comAethlon Medical advances Hemopurifier study as final trial cohort nears completionJune 17, 2026 | finance.yahoo.comAethlon Medical Inc (AEMD) Q4 2026 Earnings Call Highlights: Strategic Advances Amid Financial ...June 17, 2026 | finance.yahoo.comSee More Headlines AEMD Stock Analysis - Frequently Asked Questions How have AEMD shares performed this year? Aethlon Medical's stock was trading at $2.77 at the beginning of 2026. Since then, AEMD stock has decreased by 76.7% and is now trading at $0.6450. How were Aethlon Medical's earnings last quarter? Aethlon Medical, Inc. (NASDAQ:AEMD) posted its earnings results on Thursday, February, 12th. The medical equipment provider reported ($2.45) EPS for the quarter, missing the consensus estimate of ($2.01) by $0.44. Read the conference call transcript. When did Aethlon Medical's stock split? Shares of Aethlon Medical reverse split before market open on Thursday, October 5th 2023.The 1-10 reverse split was announced on Wednesday, October 4th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Aethlon Medical? Shares of AEMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aethlon Medical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aethlon Medical investors own include Advanced Micro Devices (AMD), Nokia (NOK), NVIDIA (NVDA), Pfizer (PFE), Plug Power (PLUG), Organigram Global (OGI). Company Calendar Last Earnings2/12/2026Today7/17/2026Next Earnings (Estimated)8/12/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (8m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 AEMD's financial health is in the Red zone, according to TradeSmith. AEMD has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - HMO Sub-IndustryMedical Equipment Current SymbolNASDAQ:AEMD CIK882291 Webwww.aethlonmedical.com Phone(858) 459-7800FaxN/AEmployees10Year Founded1998Profitability EPS (Trailing Twelve Months)($14.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.15 million Net MarginsN/A Pretax MarginN/A Return on Equity-137.73% Return on Assets-105.87% Debt Debt-to-Equity RatioN/A Current Ratio3.85 Quick Ratio3.85 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.11 per share Price / Book0.21Miscellaneous Outstanding Shares2,371,000Free Float2,354,000Market Cap$1.56 million OptionableNo Data Beta1.41 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:AEMD) was last updated on 7/17/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aethlon Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aethlon Medical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
